Alterity Therapeutics Lim... (ATHE)
NASDAQ: ATHE
· Real-Time Price · USD
4.09
-0.30 (-6.83%)
At close: Sep 25, 2025, 3:59 PM
4.05
-1.10%
After-hours: Sep 25, 2025, 04:04 PM EDT
-6.83% (1D)
Bid | 4.04 |
Market Cap | 37.12M |
Revenue (ttm) | 3.72M |
Net Income (ttm) | -19.79M |
EPS (ttm) | -0.75 |
PE Ratio (ttm) | -5.46 |
Forward PE | -5.16 |
Analyst | Strong Buy |
Dividends | n/a |
Ask | 4.15 |
Volume | 34,767 |
Avg. Volume (20D) | 78,606 |
Open | 4.21 |
Previous Close | 4.39 |
Day's Range | 4.01 - 4.21 |
52-Week Range | 1.00 - 7.00 |
Beta | 0.36 |
Ex-Dividend Date | n/a |
About ATHE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATHE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATHE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-14.81%
Alterity Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
4 months ago
+26.45%
Alterity Therapeutics shares are trading higher after the company announced that the FDa granted it Fast Track designation for ATH434 for the treatment of Multiple System Atrophy.